Modality
mAb
MOA
BCL-2i
Target
CFTR
Pathway
PI3K/AKT
IgAN
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
Dec 2023
→ Jul 2029
Phase 2Current
NCT08050940
1,055 pts·IgAN
2023-12→2029-07·Active
1,055 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-203.3y awayPh3 Readout· IgAN
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2/3
Active
Catalysts
Ph3 Readout
2029-07-20 · 3.3y away
IgAN
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08050940 | Phase 2/3 | IgAN | Active | 1055 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Sovarelsin | BioMarin | Phase 2 | CFTR |